MCMathieu Cinier

Mathieu Cinier

*This is an algorithmically generated author record based on publicly available information.

Mathieu Cinier has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ultrafast tyrosine-based cell membrane modification via diazonium salts: a new frontier for biomedical applications

    by Mohammed Bouzelha, Karine Pavageau, Sarah Renault, Enora Ferron, Nicolas Jaulin, Maia Marchand, Dimitri Alvarez-Dorta, Roxanne Peumery, Mathieu Scalabrini, Héloïse Delépée, et al.

    In this study, we present an ultrafast, efficient, and broadly applicable strategy for cell membrane modification via tyrosine bioconjugation using diazonium salt derivatives. This chemical approach enables both one-step and two-step functionalization of adherent, suspension, and primary cells with diverse ligands, including imaging probes, carbohydrates, biotin, and proteins, without inducing cytotoxicity or immune activation. Membrane engineering through bioconjugation is emerging as a valuable tool in biomedical research, given the cell membrane’s central role in signaling, transport, and cell-cell interactions. Compared to traditional glyco-engineering methods that often require multiday incubations and can cause cellular stress, our approach achieves precise and high-density grafting in less than one hour, with improved reproducibility and biological compatibility. Importantly, we demonstrate that this strategy can be applied to a variety of cell types, encompassing both immortalized cell lines and primary cells, notably Peripheral Blood Mononuclear Cells (PBMCs) and human effector cells such as natural killer (NK) cells, to enhance their cytotoxic function against EGFR-positive cancer cells via surface-conjugated Nanofitin. Moreover, we show that the bioconjugated signal diminishes over time due to cell division, offering a self-limiting alternative to permanent genetic modifications such as CAR-T, thereby mitigating risks associated with overly prolonged immune activation. Finally, the feasibility of storing pre-functionalized cells at -80 °C expands the practicality of this platform for future ready-to-use applications. Together, these features make our method a compelling alternative to current technologies for applications in targeted therapy, diagnostics, and cell-based immunotherapy.

  • Open Access

    Supplementary Data from Targeted Nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFR-positive mouse xenograft model

    by Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, et al.

  • Open Access

    Data from Targeted Nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFR-positive mouse xenograft model

    by Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, et al.

    Adjusting the molecular size, the valency and the pharmacokinetics of drug conjugates are as many leverages to improve their therapeutic window, notably by affecting tumor penetration, renal clearance and short systemic exposure. In that regard, small tumor-targeting ligands are gaining attention. In this study, we demonstrate the benefits of the small Nanofitin alternative scaffolds (7 kDa) as selective tumor-targeting modules for the generation of drug conjugates, focusing on Nanofitins B10 and D8 directed against the Epithelial Growth Factor Receptor (EGFR). Owing to their small size and monovalent format, the two Nanofitins displayed a fast and deep tumor penetration in EGFR-positive A431 xenografts in BALB/c nude mice after intravenous administration, yielding to a targeting of respectively 67.9%±14.1 and 98.9%±0.7 of the tumor cells as demonstrated by immunohistochemistry. Conjugation with the monomethyl auristatin E toxin provided homogeneous Nanofitin-drug conjugates, with an overall yield of ≥97%, for in vivo assessment in a curative xenograft model using bioluminescent, EGFR-positive, A431 cells in BALB/c nude mice. Internalization was found critical for efficient release of the toxin. Hence, the intravenous administration of the D8-based construct showed significant anti-tumor effect in vivo as determined by monitoring tumor volumes and bioluminescence levels over 2 months.

  • Open Access

    Supplementary Data from Targeted Nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFR-positive mouse xenograft model

    by Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, et al.

  • Open Access

    Data from Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model

    by Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, et al.

    Adjusting the molecular size, the valency and the pharmacokinetics of drug conjugates are as many leverages to improve their therapeutic window, notably by affecting tumor penetration, renal clearance, and short systemic exposure. In that regard, small tumor-targeting ligands are gaining attention. In this study, we demonstrate the benefits of the small Nanofitin alternative scaffolds (7 kDa) as selective tumor-targeting modules for the generation of drug conjugates, focusing on Nanofitins B10 and D8 directed against the EGFR. Owing to their small size and monovalent format, the two Nanofitins displayed a fast and deep tumor penetration in EGFR-positive A431 xenografts in BALB/c nude mice after intravenous administration, yielding to a targeting of respectively 67.9% ± 14.1 and 98.9% ± 0.7 of the tumor cells as demonstrated by IHC. Conjugation with the monomethyl auristatin E toxin provided homogeneous Nanofitin-drug conjugates, with an overall yield of ≥97%, for in vivo assessment in a curative xenograft model using bioluminescent, EGFR-positive, A431 cells in BALB/c nude mice. Internalization was found critical for efficient release of the toxin. Hence, the intravenous administration of the D8-based construct showed significant antitumor effect in vivo as determined by monitoring tumor volumes and bioluminescence levels over 2 months.

  • Open Access

    Data from Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model

    by Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, et al.

    Adjusting the molecular size, the valency and the pharmacokinetics of drug conjugates are as many leverages to improve their therapeutic window, notably by affecting tumor penetration, renal clearance, and short systemic exposure. In that regard, small tumor-targeting ligands are gaining attention. In this study, we demonstrate the benefits of the small Nanofitin alternative scaffolds (7 kDa) as selective tumor-targeting modules for the generation of drug conjugates, focusing on Nanofitins B10 and D8 directed against the EGFR. Owing to their small size and monovalent format, the two Nanofitins displayed a fast and deep tumor penetration in EGFR-positive A431 xenografts in BALB/c nude mice after intravenous administration, yielding to a targeting of respectively 67.9% ± 14.1 and 98.9% ± 0.7 of the tumor cells as demonstrated by IHC. Conjugation with the monomethyl auristatin E toxin provided homogeneous Nanofitin-drug conjugates, with an overall yield of ≥97%, for in vivo assessment in a curative xenograft model using bioluminescent, EGFR-positive, A431 cells in BALB/c nude mice. Internalization was found critical for efficient release of the toxin. Hence, the intravenous administration of the D8-based construct showed significant antitumor effect in vivo as determined by monitoring tumor volumes and bioluminescence levels over 2 months.

  • Open Access

    Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model

    by Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, et al.

    Adjusting the molecular size, the valency and the pharmacokinetics of drug conjugates are as many leverages to improve their therapeutic window, notably by affecting tumor penetration, renal clearance, and short systemic exposure. In that regard, small tumor-targeting ligands are gaining attention. In this study, we demonstrate the benefits of the small Nanofitin alternative scaffolds (7 kDa) as selective tumor-targeting modules for the generation of drug conjugates, focusing on Nanofitins B10 and D8 directed against the EGFR. Owing to their small size and monovalent format, the two Nanofitins displayed a fast and deep tumor penetration in EGFR-positive A431 xenografts in BALB/c nude mice after intravenous administration, yielding to a targeting of respectively 67.9% ± 14.1 and 98.9% ± 0.7 of the tumor cells as demonstrated by IHC. Conjugation with the monomethyl auristatin E toxin provided homogeneous Nanofitin-drug conjugates, with an overall yield of ≥97%, for in vivo assessment in a curative xenograft model using bioluminescent, EGFR-positive, A431 cells in BALB/c nude mice. Internalization was found critical for efficient release of the toxin. Hence, the intravenous administration of the D8-based construct showed significant antitumor effect in vivo as determined by monitoring tumor volumes and bioluminescence levels over 2 months.


  • Open Access

    Albumin binding Nanofitins, a new scaffold to extend half-life of biologics – a case study with exenatide peptide

    by Nadine Michot, Aurélia Guyochin, Mathieu Cinier, Chloé Savignard, Olivier Kitten, Marie-Hélène Pascual, Stéphanie Pouzieux, Marie-Laure Ozoux, Patrick Verdier, Pascale Vicat, et al.